Name: REGENERON PHARMACEUTICALS (REGN) Stock
Brand: REGENERON PHARMACEUTICALS
Rating: 7 (3 reviews)

REGN Latest News, Press Relases and Analysis

All

Press Releases

13 days ago - By: Chartmill - Mentions: SHW NUE BRO ARE ...

Uncover the latest developments among S&P500 stocks in today's session.

13 days ago - By: Chartmill - Mentions: SHW NUE BRO ARE ...

Explore the top gainers and losers within the S&P500 index in today's session.

2 days ago - By: Investor's Business Daily - Mentions: MRK AMGN SNY

Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60%

2 days ago - By: Regeneron Pharmaceuticals, Inc.

Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet

2 days ago - By: Regeneron Pharmaceuticals, Inc.

Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet

3 days ago - By: Zacks Investment Research - Mentions: ANIP ACAD NTLA

Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble

3 days ago - By: Regeneron Pharmaceuticals, Inc.

Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review

3 days ago - By: Regeneron Pharmaceuticals, Inc.

Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review

4 days ago - By: Benzinga

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years

5 days ago - By: Zacks Investment Research - Mentions: BEAM FOLD RARE

Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y

6 days ago - By: Benzinga

Looking Into Regeneron Pharmaceuticals Inc's Recent Short Interest

7 days ago - By: Regeneron Pharmaceuticals, Inc.

Regeneron Announces Investor Conference Presentations

7 days ago - By: Regeneron Pharmaceuticals, Inc.

Regeneron Announces Investor Conference Presentations

7 days ago - By: The Motley Fool - Mentions: NVO LLY

2 Beaten-Down Stocks That Could Be About to Rally

10 days ago - By: Regeneron Pharmaceuticals, Inc.

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award

10 days ago - By: Regeneron Pharmaceuticals, Inc.

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award

13 days ago - By: The Motley Fool

Regeneron (REGN) Q3 2025 Earnings Call Transcript

13 days ago - By: Chartmill - Mentions: SHW ARE UPS RCL ...

These S&P500 stocks are gapping in today's session

13 days ago - By: Chartmill - Mentions: SHW IVZ ARE UNH ...

These S&P500 stocks that are showing activity before the opening bell on Tuesday.

13 days ago - By: Investor's Business Daily

Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts

13 days ago - By: Chartmill

Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 2025 Earnings Beat Estimates

13 days ago - By: Regeneron Pharmaceuticals, Inc.

Regeneron Reports Third Quarter 2025 Financial and Operating Results

13 days ago - By: Regeneron Pharmaceuticals, Inc.

Regeneron Reports Third Quarter 2025 Financial and Operating Results

18 days ago - By: Zacks Investment Research

Exploring Analyst Estimates for Regeneron (REGN) Q3 Earnings, Beyond Revenue and EPS

18 days ago - By: Zacks Investment Research - Mentions: ALNY ETNB

REGENERON PHARMACEUTICALS (REGN) Stock News

REGN Latest News, Press Relases and Analysis

Uncover the latest developments among S&P500 stocks in today's session.

Explore the top gainers and losers within the S&P500 index in today's session.

Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60%

Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet

Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet

Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble

Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review

Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years

Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y

Looking Into Regeneron Pharmaceuticals Inc's Recent Short Interest

Regeneron Announces Investor Conference Presentations

Regeneron Announces Investor Conference Presentations

2 Beaten-Down Stocks That Could Be About to Rally

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award

Regeneron (REGN) Q3 2025 Earnings Call Transcript

These S&P500 stocks are gapping in today's session

These S&P500 stocks that are showing activity before the opening bell on Tuesday.

Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts

Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 2025 Earnings Beat Estimates

Regeneron Reports Third Quarter 2025 Financial and Operating Results

Regeneron Reports Third Quarter 2025 Financial and Operating Results

Exploring Analyst Estimates for Regeneron (REGN) Q3 Earnings, Beyond Revenue and EPS

RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised